RAFAEL HOLDINGS, INC. Selling Expense
RAFAEL HOLDINGS, INC. (RFL) reported Selling Expense of $307.91 million for the 3-month period ending 2024-01-31, per its 10-Q filed 2024-03-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingExpense · last filed 2025-06-11
- RAFAEL HOLDINGS, INC. selling expense for the quarter ending 2024-01-31 was $307.91M, a 99900.00% increase year-over-year.
- RAFAEL HOLDINGS, INC. selling expense for the quarter ending 2023-07-31 was $307.61M.
- RAFAEL HOLDINGS, INC. selling expense for the quarter ending 2023-04-30 was -$307.61M.
- RAFAEL HOLDINGS, INC. selling expense for the quarter ending 2023-01-31 was $307.91K.
| Period end | Selling Expense | Selling Expense as first filed | Selling Expense 3 month | Selling Expense 3 month as first filed | Selling Expense 6 month | Selling Expense 9 month | Selling Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2024-01-31 | $307.91M 10-Q · filed 2024-03-14 | $307.91M 10-Q · filed 2024-03-14 | |||||
| 2023-07-31 | $307.61M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-12-14 | $0.00 derived: sum of 2 quarters · filed 2023-12-14 | $307.91K derived: sum of 3 quarters · filed 2023-12-14 | $307.91M 10-Q · filed 2023-12-14 | |||
| 2023-04-30 | -$307.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | -$307.30M derived: sum of 2 quarters · filed 2023-06-13 | $307.91K 10-Q · filed 2023-06-13 | ||||
| 2023-01-31 | $307.91K 10-Q · filed 2023-06-13 | $307.91M 10-Q · filed 2023-03-14 | $307.91M 10-Q · filed 2023-03-14 | ||||
| 2023-01-27 | $307.91K 10-Q · filed 2025-06-11 | $307.91M 10-Q · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |